文献速递妇科

经阴道射频消融治疗有症状子宫肌瘤的疗效、并发症及治疗反应预测因素

Efficacy, Complications, and Factors Predictive of Response to Treatment with Transvaginal Radiofrequency Ablation for Symptomatic Uterine Myomas.
PubMed 文献 · J Minim Invasive Gynecol · 2022-01-26

这项前瞻性病例系列在西班牙格拉纳达一家三级医院纳入59例子宫肌瘤患者,评估经阴道射频消融的疗效与安全性。结果显示出血相关变量在0、2、6、12个月均显著改善,症状严重程度评分在12个月显著改善,肌瘤平均体积在2、6、12个月显著降低,12个月平均缩小超过80%。患者年龄和初始肌瘤大小是治疗结局的预测因素。

要点

  • 经阴道射频消融后出血相关变量在0、2、6、12个月均显著改善。
  • 肌瘤平均体积在2、6、12个月显著降低,12个月平均缩小超过80%。
  • 患者年龄和初始肌瘤大小是治疗结局的预测因素。

核心结论

  • 经阴道射频消融是治疗子宫肌瘤有效且安全的技术。
  • 患者年龄和肌瘤初始大小影响治疗结局。

研究设计与样本

  • 前瞻性病例系列,在西班牙格拉纳达的Virgen de las Nieves大学医院(一家三级中心)开展,纳入59例子宫肌瘤患者,干预为经阴道射频消融。

主要发现

  • 出血相关所有分析变量在0、2、6、12个月均显示症状有统计学显著改善。
  • 症状严重程度量表评分在术后12个月显著改善。
  • 肌瘤平均体积在治疗后2、6、12个月显著降低(p<.05)。
  • 12个月时肌瘤体积平均缩小超过80%。
  • 患者年龄和初始肌瘤大小被确定为治疗结局的预测因素。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY OBJECTIVE: Transvaginal radiofrequency ablation is a minimally invasive treatment for myomas in women who wish to preserve their uterus. This study aimed to evaluate the efficacy and safety of transvaginal radiofrequency to treat myomas and to identify factors predictive of the response to treatment. DESIGN: Prospective case series. SETTING: Virgen de las Nieves University Hospital, a tertiary center in Granada, Spain. PATIENTS: The participants were 59 patients with myomas. INTERVENTIONS: Transvaginal radiofrequency ablation. MEASUREMENTS AND MAIN RESULTS: The variables recorded were personal (age and type of myoma), procedure dependent (pain, need for analgesia, duration of sick leave, procedure duration, and complications), clinical (total days of menstrual bleeding and days of heavy menstrual bleeding), and score on the symptom severity scale of the Uterine Fibroid Symptom and Quality of Life Questionnaire. Myoma volume was determined by ultrasonography. Changes in clinical variables and myoma volume were analyzed 2, 6, and 12 months after the procedure. Moreover, the influence of age, initial myoma size, type of myoma, and duration of the procedure on the outcomes of treatment were analyzed. Statistically significant improvements in symptoms were seen in all variables analyzed for bleeding at 0, 2, 6, and 12 months, and a significant improvement was seen in the symptom severity scale score 12 months after the procedure. Mean myoma volume (in milliliters) was significantly lower 2, 6, and 12 months after treatment (p <.05). At 12 months, the mean reduction in myoma volume was more than 80%. Patient age and initial myoma size were identified as factors predictive of the outcomes. CONCLUSION: Transvaginal radiofrequency ablation was an effective and safe technique for the treatment of myomas. The patient's age and initial size of the myoma influenced the outcome of treatment.

来源:J Minim Invasive Gynecol,查看原文。版权归原作者所有。

引用

  1. Santalla-Hernández Á, Naveiro-Fuentes M, Benito-Villena R, et al. Efficacy, Complications, and Factors Predictive of Response to Treatment with Transvaginal Radiofrequency Ablation for Symptomatic Uterine Myomas. J Minim Invasive Gynecol. 2022. PMID: 35091094. doi:10.1016/j.jmig.2022.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。